Ann: Phase 2a Study Shows BTX 1801 Eradicates S. Aureus, page-214

For clarification, there were 66 people in the study, 22 in the ointment group, 22 in the gel group, and 22 in the vehicle group. In the ointment group consisting of 22 people, at day 7, 16.76 people (22 x 76.2%) showed no signs of staph in their nose. Of the same group, day 12 saw 8.38 people (22 x 38.1%) with no signs of staph in their nose. By day 28 (23 days after treatment had ended) 5.23 (22 x 23.8%) had no signs of staph in their nose which means that staph was found in 17 people's nose in the ointment group of 22 participants.

What BOT will need to aim for is a dosage period and amount that improves upon the eradication rate overtime. These results show that there is something there, but they need improvement in my view before this will become commercially viable. Still, it's fantastic news that there is an alternative treatment in the pipeline and nobody can take this away from the BOT team.

The science will progress.

GLTAH.